His primary scientific interests are in Physical therapy, Parkinson's disease, Severity of illness, Disease and Internal medicine. His Physical therapy research is multidisciplinary, relying on both MEDLINE, Rating scale, Randomized controlled trial, Levodopa and Unified Parkinson's disease rating scale. His biological study spans a wide range of topics, including Psychiatry, Depression and Late onset.
He combines subjects such as Clinical psychology, Punding, Impulse control disorder and Dopamine dysregulation syndrome with his study of Severity of illness. His work carried out in the field of Disease brings together such families of science as Physical medicine and rehabilitation and Intensive care medicine. The Internal medicine study combines topics in areas such as Gastroenterology and Cardiology.
The scientist’s investigation covers issues in Parkinson's disease, Disease, Psychiatry, Internal medicine and Deep brain stimulation. He has researched Parkinson's disease in several fields, including Physical therapy, Central nervous system disease, Neuroscience and Dementia. The study incorporates disciplines such as Unified Parkinson's disease rating scale and Rating scale in addition to Physical therapy.
In Disease, Matthew B. Stern works on issues like Intensive care medicine, which are connected to MEDLINE. His study looks at the relationship between Psychiatry and fields such as Clinical psychology, as well as how they intersect with chemical problems. Matthew B. Stern has included themes like Randomized controlled trial, Surgery, Quality of life and Physical medicine and rehabilitation in his Deep brain stimulation study.
His scientific interests lie mostly in Parkinson's disease, Disease, Internal medicine, Psychiatry and Deep brain stimulation. His research in Parkinson's disease intersects with topics in Cognition, Neuroscience, Dementia, Cognitive decline and Biomarker. The Disease study which covers Clinical research that intersects with Rest tremor.
His study focuses on the intersection of Internal medicine and fields such as Oncology with connections in the field of Disease progression and MEDLINE. The various areas that Matthew B. Stern examines in his Psychiatry study include Parkinsonism and Intensive care medicine. His work carried out in the field of Deep brain stimulation brings together such families of science as Physical therapy and Randomized controlled trial.
Matthew B. Stern spends much of his time researching Parkinson's disease, Internal medicine, Disease, Randomized controlled trial and Psychiatry. His Parkinson's disease study combines topics from a wide range of disciplines, such as Disease progression, Prodrome, Oncology and MEDLINE. In his study, Parkinsonism is inextricably linked to Physical therapy, which falls within the broad field of Internal medicine.
Disease and Severity of illness are commonly linked in his work. His Randomized controlled trial research incorporates elements of Anesthesia, Adverse effect and Deep brain stimulation. His Psychiatry study combines topics in areas such as Lewy body, Gold standard, Cognitive psychology and Cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Christopher G. Goetz;Barbara C. Tilley;Stephanie R. Shaftman;Glenn T. Stebbins.
Movement Disorders (2008)
MDS clinical diagnostic criteria for Parkinson's disease
Ronald B. Postuma;Daniela Berg;Matthew Stern;Werner Poewe.
Movement Disorders (2015)
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial
Frances M. Weaver;Frances M. Weaver;Kenneth Follett;Matthew Stern;Matthew Stern;Kwan Hur.
Variable expression of Parkinson's disease A base‐line analysis of the DAT ATOP cohort
Joseph Jankovic;Michael P McDermott;Jonathan T Carter;Susan A Gauthier.
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Clifford W. Shults;David Oakes;Karl Kieburtz;M. Flint Beal.
JAMA Neurology (2002)
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
Kenneth A. Follett;Kenneth A. Follett;Frances M. Weaver;Matthew Stern;Kwan Hur.
The New England Journal of Medicine (2010)
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
Christopher G. Goetz;Stanley Fahn;Pablo Martinez-Martin;Werner Poewe.
Movement Disorders (2007)
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf.
Progress in Neurobiology (2011)
The scientific and clinical basis for the treatment of Parkinson disease (2009)
C. Warren Olanow;Matthew B. Stern;Kapil Sethi.
MDS research criteria for prodromal Parkinson's disease
Daniela Berg;Ronald B. Postuma;Charles H. Adler;Bastiaan R. Bloem.
Movement Disorders (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: